Pelthos Therapeutics Inc. (PTHS) stock
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.10+0.26 (+3.80%)
Close on Nov 18, 2026Market cap $27.18MP/E –Yield –
Pelthos Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Pelthos Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $43.30M. For fiscal 2025 it was $16.80M.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.80M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.60M | – |
| Q1 FY2026 | Mar 31, 2026 | $10.91M | – |
| Q4 FY2025 | Dec 31, 2025 | $9.39M | – |
| Q3 FY2025 | Sep 30, 2025 | $7.41M | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
See a number that looks wrong?